Dean Robert M, Bishop Michael R
Medical Oncology Clinical Research Unit, Experimental Transplant and Immunology Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 12N226, 10 Center Drive, MSC 1906, Bethesda, MD 20892, USA.
Curr Hematol Rep. 2003 Jul;2(4):287-94.
Despite progress in allogeneic hematopoietic stem cell transplantation during the past three decades, graft-versus-host disease (GVHD) still contributes substantially to transplant-related morbidity and mortality. Although current strategies to prevent or treat this complication remain unsatisfactory, new insights into its pathophysiology have yielded novel targets for GVHD prophylaxis and therapy. Regulating GVHD without sacrificing beneficial graft-versus-tumor reactivity and immune competence continues to be an elusive goal. Many promising new interventions have undergone limited clinical evaluation, but controlled studies are needed to define their roles more clearly. Refinements in clinical grading systems and prognostic indices will facilitate the study of new strategies in GVHD prevention and treatment.
尽管在过去三十年中异基因造血干细胞移植取得了进展，但移植物抗宿主病（GVHD）仍然是导致移植相关发病率和死亡率的重要因素。虽然目前预防或治疗这种并发症的策略仍不尽人意，但对其病理生理学的新认识为GVHD的预防和治疗带来了新的靶点。在不牺牲有益的移植物抗肿瘤反应性和免疫能力的情况下调节GVHD仍然是一个难以实现的目标。许多有前景的新干预措施的临床评估有限，需要进行对照研究以更清楚地确定它们的作用。临床分级系统和预后指标的完善将有助于GVHD预防和治疗新策略的研究。
